Key Highlights: Implications: Piramal Pharma’s move to 74% ownership of Yapan Bio for ₹76 crore turns the Hyderabad CDMO into a subsidiary, giving Piramal tighter control over Yapan’s process developm...
Key Highlights: Implications: Optimus Pharma’s DCGI approval for Tapinarof Cream 1% gives India its first locally manufactured, non‑steroidal topical for adult plaque psoriasis, offering dermatologist...
Key Highlights: Implications: Biodeal’s ₹385 crore raise gives it the capital to scale up manufacturing, add new products, and enter more regulated markets, which should help it win bigger, longer-ter...
Summary The Top 10 R&D Spending Indian Biopharma Companies of 2026 reflect the country’s growing commitment to pharmaceutical innovation, advanced drug develop...
Key Highlights: Implications: By consolidating three injectable-focused entities under one legal umbrella, Aurobindo can streamline manufacturing, R&D, and commercial operati...
Key Highlights: Implications: The expansion makes Turbhe more competitive for high-potency peptides, HPAPIs, and biomolecules, helping Piramal attract programs that need safe, sm...
Key Highlights: Implications: Emcure’s move to take Gennova to 100% ownership and fold it under the “One Emcure” framework tightens control over a strategically important biologi...
Key Highlights: Implications: Aragen is using ChemiSHE to make gender diversity a visible part of its R&D operating model: an all‑women chemistry synthesis lab in ...
